Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 14/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 13/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 12/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 12/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 11/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6965134 | 0.92 | ADRA2A (0.85) | ADRA2AADRA2CADRA2BADRA1DADRA1B | |
| SCHEMBL3353162 | 0.83 | ADRA2A (0.71) | ADRA2AADRA2CADRA2BADRA1DADRA1B | |
| Brimonidine SCHEMBL24670 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2CADRA2BADRA1DADRA1B | |
| Brimonidine SCHEMBL29374525 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2CADRA2BADRA1DADRA1B | |
| SCHEMBL29171467 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2CADRA2BADRA1DADRA1B | |
| Brimonidine SCHEMBL20511531 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2CADRA2BADRA1DADRA1B | |
| Fumaric Acid SCHEMBL27521800 | 0.82 | ADRA2A (0.69) | ADRA2AADRA2CADRA2BADRA1DADRA1B | |
| Brimonidine SCHEMBL1685506 | 0.82 | ADRA2A (0.97) | ADRA2AADRA2CADRA2BADRA1DADRA1B | |
| Brimonidine SCHEMBL22616115 | 0.82 | ADRA2A (0.97) | ADRA2AADRA2CADRA2BADRA1DADRA1B | |
| SCHEMBL7742092 | 0.81 | ADRA2A (0.67) | ADRA2AADRA2CADRA2BADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3157408-B1 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | ALCON INC (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4714407-A2 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | Alcon Inc. (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250057694-A1 | DEVICES AND METHODS TO PROVIDE HANDS FREE SCLERAL DEPRESSION AND ILLUMINATION DURING OPHTHALMIC PROCEDURES | Ganihand, LLC (US) | 2025-02-20 | — | — | US | disclosed |
| US-20240374573-A1 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC | 2024-11-14 | — | — | US | disclosed |
| WO-2024226608-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | AGLAEAPHARMA INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20220175797-A1 | OPHTHALMOLOGIC IRRIGATION SOLUTIONS AND METHOD | OMEROS CORP (US) | 2022-06-09 | — | — | US | disclosed |
| US-11266395-B2 | Devices and methods to provide hands free scleral depression during ophthalmic procedures | Ganihand, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-8455492-B2 | Methods for treating retinal diseases | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455492-B2 | Methods for treating retinal diseases | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| CN-1137755-A | 6-(2-imidazolinylamino) quinoxaling compounds useful as alpha-2 adrenoceptor agonists | PROCTER & GAMBLE (US) | 1996-12-11 | — | — | CN | disclosed |
| EP-0735877-A1 | 6-(2-IMIDAZOLINYLAMINO)QUINOXALINE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5561132-A | ADMINISTERING TO ALTER RATE OF FLUID TRANSPORT IN GASTROINTESTINAL TRACT | ALLERGAN (US) | 1996-10-01 | — | — | US | disclosed |
| US-5552403-A | ANTIISCHEMIC AGENTS | ALLERGAN (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0723447-A1 | METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES | Allergan (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995016449-A1 | 6-(2-IMIDAZOLINYLAMINO)QUINOXALINE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1995-06-22 | — | — | WO | disclosed |
| EP-0426390-B1 | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure | ALLERGAN INC (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1995010280-A1 | METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES | ALLERGAN (US) | 1995-04-20 | — | — | WO | disclosed |
| US-5021416-A | Glaucoma | ALLERGAN, INC. (US) | 1991-06-04 | — | — | US | disclosed |
| EP-0426390-A2 | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure | ALLERGAN, INC. (US) | 1991-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374573-A1 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ADRB2, ADRA2C, ADRA2B | ADRA2A 4/4885ADRA2C 2/4885ADRA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.